Arvinas and Pfizer report Phase 3 VERITAC-2 hit: vepdegestrant improves PFS in ESR1m breast cancer; ITT miss

ARVINAS, INC.

Vepdegestrant met primary endpoint in ESR1m population: statistically significant PFS improvement, exceeded target HR of 0.60.
ITT population did not achieve statistical significance for PFS.
Overall survival not mature (<25% of required events); trial continuing.
Safety profile consistent with prior studies; detailed results to be submitted to medical meeting and regulators.
First PROTAC degrader to show Phase 3 clinical benefit; Fast Track designation previously granted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.